Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company’s lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
Metrics to compare | HEMO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHEMOPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.4x | −3.4x | −0.6x | |
PEG Ratio | −0.07 | −0.02 | 0.00 | |
Price/Book | 4.0x | 2.2x | 2.6x | |
Price / LTM Sales | - | 12.4x | 3.1x | |
Upside (Analyst Target) | - | 185.6% | 54.6% | |
Fair Value Upside | Unlock | 4.2% | 7.7% | Unlock |